Identity and synonyms
Lys-Pro-Val (KPV), verified in FDA assessment; modified acetylated/amidated products require separate identity.
Synonyms: Lys-Pro-Val
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Tripeptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
PepT1-mediated uptake and inflammatory signaling effects in experimental intestinal systems.
Evidence and critical reading
Reported scientific and empirical uses
Gut and barrier · Immune modulation and inflammation
Handbooks describe oral use and combination with BPC-157; catalogs also include it in blends. Those routes and combinations need their own evidence.
Human evidence
No clinical efficacy established by the reviewed sources; avoid claiming treatment of Crohn disease or generic “leaky gut.”
Preclinical evidence
Cell experiments and mouse colitis models support a research hypothesis.
Critical reading and limitations
The PepT1 study includes cell lines and induced mouse colitis. It does not establish clinical response in human inflammatory bowel disease. A published oral quantity does not justify injection or transfer results to KLOW.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
500 mcg · Amount per administration
- Frequency
- Twice daily
- Duration
- Not stated on selected page.
- Route
- Oral
- Context
- Described intestinal/anti-inflammatory support.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 70 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US: FDA scientific assessment is not approval.
Adverse effects and unknowns
No adequate human safety or interaction characterization; lack of reports is not reassurance.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID18061177 · Cells and mouse experiments
Cell lines and induced mouse colitis.
Culture and oral administration in mice.
PepT1-mediated anti-inflammatory signals.
Does not confirm human oral or injectable clinical efficacy.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
KPV · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID18061177
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D.
October 16, 2026
- R02
- R14
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026